17 June 2023 in Journal of Diabetes
MAMohammad Reza Afsharmanesh
Mohammad Reza Afsharmanesh
Type 2 diabetes mellitus (T2DM) and its associated complications have become a crucial public health concern in the world. According to the literature, chronic inflammation and the progression of T2DM have a close relationship. Accumulated evidence suggests that inflammation enhances the insulin secretion lost by islets of Langerhans and the resistance of target tissues to insulin action, which are two critical features in T2DM development. Based on recently highlighted research that plasma concentration of inflammatory mediators such as tumor necrosis factor α and interleukin‐6 are elevated in insulin‐resistant and T2DM, and it raises novel question marks about the processes causing inflammation in both situations. Over the past few decades, microRNAs (miRNAs), a class of short, noncoding RNA molecules, have been discovered to be involved in the regulation of inflammation, insulin resistance, and T2DM pathology. These noncoding RNAs are specifically comprised of RNA‐induced silencing complexes and regulate the expression of specific protein‐coding genes through various mechanisms. There is extending evidence that describes the expression profile of a special class of miRNA molecules altered during T2DM development. These modifications can be observed as potential biomarkers for the diagnosis of T2DM and related diseases. In this review study, after reviewing the possible mechanisms involved in T2DM pathophysiology, we update recent information on the miRNA roles in T2DM, inflammation, and insulin resistance.
18 July 2023 in Health Science Reports
Background: Fibrillin is one of the extracellular matrix glycoproteins and participates in forming microfibrils found in many connective tissues. The microfibrils enable the elasticity and stretching properties of the ligaments and support connective tissues. There are three isoforms of fibrillin molecules identified in mammals: fibrillin 1 (FBN1), fibrillin 2 (FBN2), and fibrillin 3.Objective: Multiple studies have shown that mutations in these genes or changes in their expression levels can be related to various diseases, including cancers. In this study, we focus on reviewing the role of the fibrillin family in multiple cancers.Methods and Results: We performed a comprehensive literature review to search PubMed and Google Scholar for studies published so far on fibrillin gene expression and its role in cancers. In this review, we have focused on the expression of FBN1 and FBN2 genes in cancers such as the lung, intestine, ovary, pancreatic ductal, esophagus, and thyroid.Conclusion: Altogether various studies showed higher expression of fibrillins in different tumor tissues correlated with the patient's survival. However, there are controversial findings, as some other cancers showed hypermethylated FBN promoters with lower gene expression levels.
22 February 2023 in BioMedicine
Background and Aim: Adenosine A1 receptor (AA1R) has been shown to have an inhibitory effect on cell growth in several cancers; however, its function in esophageal cancer is still unclear. In this study, we examined the effect of AA1R on cell growth and apoptosis in esophageal cancer cells. Materials and methods: In this study, YM-1 and KYSE-30 esophageal cancer cell lines were cultured. AA1R gene expression was determined by quantitative Real-time Polymerase Chain Reaction (qRT-PCR). As well, the AA1R antagonist (DPCPX) effect on cell viability was evaluated by the MTT assay. Moreover, apoptosis was assessed by annexin-V and propidium iodide staining, and the caspase-3/7 activity assay kit. Result: qRT-PCR results indicated that the AA1R was expressed in YM-1 and KYSE30 cells. In addition, DPCPX significantly decreased cell proliferation in both cell lines. Furthermore, the A1AR antagonist induced apoptosis in KYSE-30 and YM-1 cells. After treatment of both cell lines with DPCPX, the caspase 3/7 activity was increased. Conclusion: Our finding indicates the AA1R antagonist induces apoptosis through caspase 3/7 activation and can be considered a potential target in esophageal cancer therapy.
23 January 2024 in Jundishapur Journal of Natural Pharmaceutical Products
MAMohammad Reza Afsharmanesh
Mohammad Reza Afsharmanesh
+1
Background: Okra (Abelmoschus esculentus) has garnered scientific attention for its beneficial effects on various chronic disorders, including type 2 diabetes mellitus. Objectives: The current study was designed and conducted to assess the influence of whole okra fruit powder on the serum levels of specific biochemical parameters in individuals with pre-diabetes. Methods: Seventy pre-diabetic patients, aged 30 - 55 years, were divided into two groups: The okra group (n = 35, fasting plasma glucose: 116.26 ± 6.02) and the placebo group (n = 35, fasting plasma glucose: 112.26 ± 5.8). The okra group received 3000 mg of okra capsules daily for eight weeks, while the placebo group received placebo capsules. Liver function, renal markers, and lipid profiles were assessed at both the baseline and the end of the experiment using a spectrophotometer. The impact of the okra intervention on biochemical parameters was determined using parametric or non-parametric analysis of covariance (ANCOVA). Results: The serum levels of total cholesterol, low-density lipoprotein cholesterol, liver transaminases, and uric acid were significantly lower in the okra group compared to the placebo group. Conversely, the high-density lipoprotein cholesterol levels were significantly higher in the okra group than in the placebo group. However, there were no statistically significant differences between the two groups regarding triglycerides, creatinine, blood urea nitrogen, and alkaline phosphatase levels. Conclusions: The consumption of okra effectively improved the lipid profile and certain serum parameters (alanine transaminase, aspartate transaminase, and uric acid) related to liver and kidney health in pre-diabetic participants.
26 June 2023 in Medical Oncology
19 December 2022 in Cancer Reports
Background: Esophageal cancer (EC) is the sixth leading cause of cancer‐related death, despite many advances in treatment, the survival of patients still remains poor. In recent years, the N6‐methyladenosine (m6A) has been introduced as one of the most important modifications at the epitranscriptome level, with an important role in the mRNA regulation in various diseases, such as cancers. The m6A is regulated by different factors, including FTO as a demethylase. The m6A modification, especially through FTO overexpression has an oncogenic role in different cancer types such as EC. Recent studies showed that entacapone, a catechol‐o‐methyl transferase (COMT) inhibitor currently applied for Parkinson's disease, can inhibit FTO enzyme.Aims: In this study, we aimed to investigate the effect of entacapone as an FTO inhibitor on the m6A level and also apoptosis and cell cycle response in KYSE‐30 and YM‐1 of esophageal squamous cancer cell (ESCC) lines.Methods: Cell toxicity and IC50 of entacapone were evaluated using The MTT assay in YM‐1 and KYSE‐30 cells. Cells were treated into two groups: DMSO (control) and entacapone (mean IC50). Total RNA was extracted, and m6A levels were measured via the ELISA method. Subsequently, the apoptosis and cell cycle dys‐regulation were detected by annexin‐V‐FITC/PI staining and PI staining via flow cytometry.Results: Entacapone has the cytotoxicity effect on both esophageal cancer cell lines compared to normal PBMC cells. As well, entacapone treatment (140 μM) can induce apoptosis (KYSE‐30: 50%. YM‐1:22.6%) and has a modulatory effect on cell cycle progression in both YM‐1 and KYSE‐30 cells (p‐value<.05). However, no significant difference in the m6A concentration was observed.Conclusion: Our findings suggested that entacapone has the inhibitory effect on ESCC cell lines through induction of the apoptosis and modulation of the cell cycle without toxicity on the normal PBMC.